{
    "clinical_study": {
        "@rank": "8301", 
        "arm_group": [
            {
                "arm_group_label": "dHACM", 
                "arm_group_type": "Experimental", 
                "description": "UltraPulse laser therapy with application of dHACM"
            }, 
            {
                "arm_group_label": "Sterile 0.9% Saline Solution", 
                "arm_group_type": "Placebo Comparator", 
                "description": "UltraPulse laser therapy with application of Sterile 0.9% Saline Solution"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of dHACM (Dehydrated Human Amnion\n      Chorion Membrane) for reducing time to healing when used in post-laser recovery  following\n      ActiveFX\u2122 and DeepFx\u2122 fractionated ablative CO2 laser resurfacing of the face."
        }, 
        "brief_title": "Dehydrated Human Amnion/Chorion Membrane (dHACM) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Scarring", 
        "condition_browse": {
            "mesh_term": [
                "Cicatrix", 
                "Dehydration"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female subjects in good general health greater than 18 years of age\n\n          2. Must be willing to agree to all terms of the protocol and provide a completed and\n             signed informed consent, HIPAA and photography release forms\n\n          3. Subjects planning to undergo fractionated ablative CO2 laser resurfacing to the full\n             face\n\n          4. Subject of either Fitzpatrick Skin Types I, II or III\n\n               -  For female subjects of childbearing potential, they must have had a regular\n                  menstrual cycle prior to study entry and is willing to use an acceptable form of\n                  birth control during the entire course of the study. All systemic birth control\n                  measures must be in consistent use at least 30 days prior to entry into the\n                  study. A female is considered NOT to be of childbearing potential if she is\n                  postmenopausal for at least one (1) year, without a uterus and/or both ovaries,\n                  or has had a bilateral tubal ligation. Acceptable methods of birth control are:\n                  oral contraceptives, contraceptive patches/rings/implants Norplant,\n                  Depo-Provera, double-barrier methods (e.g. condoms and spermicide), abstinence\n                  and vasectomies of the partner.\n\n          5. Negative urine pregnancy test results at the time of study entry for females of\n             childbearing potential, if applicable\n\n          6. Must be willing to comply with study instructions and complete the entire course of\n             the study\n\n        Exclusion Criteria:\n\n          1. Any uncontrolled systemic disease that is not yet stabilized for at least one (1)\n             year\n\n          2. A significant history or current evidence of a medical, psychological or other\n             disorder that, in the investigator's opinion, would interfere with the objectives of\n             the study\n\n          3. Recently excessive exposure to sunlight or artificial UV light (e.g.: use of tanning\n             beds/booths and/or sunbathing) or expectations of tanning during the time of the\n             study or has used self-tanner within 7 days of study entry\n\n          4. History of or the presence of any skin condition/disease that might interfere with\n             the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema,\n             psoriasis, seborrheic dermatitis)\n\n          5. Active bacterial, fungal, or viral infection\n\n          6. History of Herpes Simplex Virus to the facial and/or perioral areas\n\n          7. Known allergies or sensitivities to benzocaine, lidocaine, tetracaine, PABA\n             (para-aminobenzoic acid), or other local anesthetics of the amide or ester family\n\n          8. Known allergies to gentamicin and/or streptomycin\n\n          9. Receiving any topical products containing alpha-hydroxy acids, salicylic acid, and\n             Vitamins C or E (including derivatives of Vitamins C or E) on the face within 14 days\n             prior to or during the study period, other than the ingredients of the study products\n\n         10. Receiving and/or has had a microdermabrasion (light or medium skin peel) treatment on\n             their face within 30 days prior to or during the study period\n\n         11. Using any topical tretinoin product or derivative on their face within 12 weeks prior\n             to or during the study period\n\n         12. Receiving a chemical peel, any systemic steroids, a non-ablative laser, light or\n             radio frequency treatment and/or has had a Dermabrasion (deep skin peel) or ablative\n             laser treatments on their face must have discontinued the drug/treatment and/or had\n             the procedure at least 3 months prior to entering the study\n\n         13. History of keloids or hypertrophic scars\n\n         14. Use of systemic retinoids, prescription or over-the-counter grade within the past\n             year\n\n         15. A female subject who is pregnant, nursing an infant or planning a pregnancy during\n             the study\n\n         16. Current participation or completed participation of a clinical research study for an\n             investigational drug or device within 30 days prior to the start of this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995604", 
            "org_study_id": "EFLR001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sterile 0.9% Saline Solution", 
                "description": "Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.", 
                "intervention_name": "Application of Sterile 0.9% Saline Solution", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "dHACM", 
                "description": "Application of dHACM to half of face after UltraPulse laser therapy.", 
                "intervention_name": "Application of dHACM", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 25, 2013", 
        "location": {
            "contact": {
                "last_name": "William F Groff, D.O.", 
                "phone": "858-657-1002"
            }, 
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92121"
                }, 
                "name": "Dermatology Cosmetic Laser Medical Associates of LaJolla, Inc."
            }, 
            "investigator": [
                {
                    "last_name": "Mitchel P Goldman, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "William F Groff, DO", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Center, Double Blinded, Placebo Controlled, Randomized, Split Face Study to Evaluate the Efficacy of dHACM (Dehydrated Human Amnion Chorion Membrane) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face", 
        "other_outcome": {
            "measure": "Pain Reduction", 
            "safety_issue": "No", 
            "time_frame": "30 Days"
        }, 
        "overall_official": {
            "affiliation": "Dermatology Cosmetic Laser Medical  Associates of La Jolla, Inc.", 
            "last_name": "Mitchel P Goldman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The time to healing for both groups will be assessed as defined by appearance and 100% epithelialization.", 
            "safety_issue": "No", 
            "time_frame": "Day 30"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Erythema, edema, crusting, and exudate will be compared between both groups.", 
            "safety_issue": "No", 
            "time_frame": "30 Days"
        }, 
        "source": "MiMedx Group, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MiMedx Group, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}